Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1962 2
1963 1
1967 1
1968 8
1969 4
1970 7
1971 1
1972 3
1973 2
1975 3
1976 4
1977 5
1978 6
1979 3
1980 5
1982 2
1983 5
1984 4
1985 1
1986 7
1987 3
1988 6
1989 3
1990 2
1991 3
1992 2
1993 6
1994 1
1995 4
1996 1
1998 1
2001 3
2003 2
2004 1
2005 2
2006 1
2007 5
2008 1
2010 2
2011 2
2013 5
2014 3
2015 3
2016 3
2017 2
2020 2
2021 5
2022 4
2023 6
2024 6
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Results by year

Filters applied: . Clear all
Page 1
Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.
Wiedemann A, Lhomme E, Huchon M, Foucat E, Bérerd-Camara M, Guillaumat L, Yaradouno M, Tambalou J, Rodrigues C, Ribeiro A, Béavogui AH, Lacabaratz C, Thiébaut R, Richert L, Lévy Y; Prevac study team. Wiedemann A, et al. Nat Commun. 2024 Sep 3;15(1):7666. doi: 10.1038/s41467-024-51453-z. Nat Commun. 2024. PMID: 39227399 Free PMC article. Clinical Trial.
Randomized Trial of Vaccines for Zaire Ebola Virus Disease.
PREVAC Study Team; Kieh M, Richert L, Beavogui AH, Grund B, Leigh B, D'Ortenzio E, Doumbia S, Lhomme E, Sow S, Vatrinet R, Roy C, Kennedy SB, Faye S, Lees S, Millimouno NP, Camara AM, Samai M, Deen GF, Doumbia M, Espérou H, Pierson J, Watson-Jones D, Diallo A, Wentworth D, McLean C, Simon J, Wiedemann A, Dighero-Kemp B, Hensley L, Lane HC, Levy Y, Piot P, Greenwood B, Chêne G, Neaton J, Yazdanpanah Y. PREVAC Study Team, et al. N Engl J Med. 2022 Dec 29;387(26):2411-2424. doi: 10.1056/NEJMoa2200072. Epub 2022 Dec 14. N Engl J Med. 2022. PMID: 36516078 Clinical Trial.
Harmonization of Vaccine Ligand Binding Assays Validation.
Dessy F, Sonderegger I, Wagner L, Buoninfante A, Wadhwa M, Agnes J, Aksyuk A, Baclin A, Bonhomme M, Cloney-Clark S, Corsaro B, Neto JT, Fries L, Gagnon L, Garofolo F, Giardina P, Green T, Guimera N, Harris S, Helmy R, Huleatt J, Ishii-Watabe A, Jaeger R, Jani D, Janssen S, Kierstead L, Makar K, Marshall JC, Mayer C, Mendes DN, Murphy R, Nadarajah S, Nolan K, Plested J, Scully I, Solstad T, Stoop J, Tan C, Verch T, Wilkins D, Xu A, Zheng L, Zhu M. Dessy F, et al. Among authors: stoop j. Bioanalysis. 2024;16(19-20):1067-1091. doi: 10.1080/17576180.2024.2411925. Epub 2024 Nov 14. Bioanalysis. 2024. PMID: 39540375
Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.
Valayer S, Alexandre M, Prague M, Beavogui AH, Doumbia S, Kieh M, Greenwood B, Leigh B, Poupelin M, Schwimmer C, Sow SO, Berry IM, Kuhn JH, Fusco D, Cauwelaert ND, Watson-Jones D, Thiébaut R, Lévy Y, Yazdanpanah Y, Richert L, Lhomme E; PREVAC study team. Valayer S, et al. Emerg Microbes Infect. 2025 Dec;14(1):0. doi: 10.1080/22221751.2024.2432353. Epub 2024 Dec 9. Emerg Microbes Infect. 2025. PMID: 39559990 Free PMC article. Clinical Trial.
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Lee AW, Liu K, Lhomme E, Blie J, McCullough J, Onorato MT, Connor L, Simon JK, Dubey S, VanRheenen S, Deutsch J, Owens A, Morgan A, Welebob C, Hyatt D, Nair S, Hamzé B, Guindo O, Sow SO, Beavogui AH, Leigh B, Samai M, Akoo P, Serry-Bangura A, Fleck S, Secka F, Lowe B, Watson-Jones D, Roy C, Hensley LE, Kieh M, Coller BG; PREVAC Study Team. Lee AW, et al. Clin Infect Dis. 2024 Apr 10;78(4):870-879. doi: 10.1093/cid/ciad693. Clin Infect Dis. 2024. PMID: 37967326 Free PMC article. Clinical Trial.
Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
Wagstaffe HR, Clutterbuck EA, Bockstal V, Stoop JN, Luhn K, Douoguih M, Shukarev G, Snape MD, Pollard AJ, Riley EM, Goodier MR. Wagstaffe HR, et al. Among authors: stoop jn. J Infect Dis. 2021 Apr 8;223(7):1171-1182. doi: 10.1093/infdis/jiz657. J Infect Dis. 2021. PMID: 31821493 Free PMC article.
Galectin-1 induces a tumor-associated macrophage phenotype and upregulates indoleamine 2,3-dioxygenase-1.
Rudjord-Levann AM, Ye Z, Hafkenscheid L, Horn S, Wiegertjes R, Nielsen MAI, Song M, Mathiesen CBK, Stoop J, Stowell S, Straten PT, Leffler H, Vakhrushev SY, Dabelsteen S, Olsen JV, Wandall HH. Rudjord-Levann AM, et al. Among authors: stoop j. iScience. 2023 May 27;26(7):106984. doi: 10.1016/j.isci.2023.106984. eCollection 2023 Jul 21. iScience. 2023. PMID: 37534161 Free PMC article.
164 results